Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. - Wikidata - awgldk - TriplyDB

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.

http://www.wikidata.org/entity/Q30399334

about

Influenza virus vaccines: lessons from the 2009 H1N1 pandemic Two years after pandemic influenza A/2009/H1N1: what have we learned?Differential influenza H1N1-specific humoral and cellular response kinetics in kidney transplant patients.Influenza vaccination in India: position paper of Indian Academy of Pediatrics, 2013.Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada.Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial.Pre- and postpandemic estimates of 2009 pandemic influenza A(H1N1) seroprotection to inform surveillance-based incidence, by age, during the 2013-2014 epidemic in Canada.Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland.Influenza vaccines: a moving interdisciplinary field.Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets.Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice Evaluation of Influenza Vaccination Efficacy: A Universal Epidemic Model.Field effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 A(H1N1) influenza: estimations from surveillance data in France.Rapid assessment of influenza vaccine effectiveness: analysis of an internet-based cohort.Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010.Vaccination against 2009 pandemic H1N1 in a population dynamical model of Vancouver, Canada: timing is everything Assessment of the variability in influenza A(H1N1) vaccine effectiveness estimates dependent on outcome and methodological approach Influenza vaccination coverage rate in children: reasons for a failure and how to go forward.H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.Prospective hospital-based case-control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009-2010 using matched hospital and test-negative controls The potential effect of temporary immunity as a result of bias associated with healthy users and social determinants on observations of influenza vaccine effectiveness; could unmeasured confounding explain observed links between seasonal influenza v Effectiveness of 1 dose of influenza A (H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 infection among school-aged children in maine.Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients.PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries.The first, second and third wave of pandemic influenza A (H1N1)pdm09 in North Denmark Region 2009-2011: a population-based study of hospitalizations.Using a Dynamic Model to Consider Optimal Antiviral Stockpile Size in the Face of Pandemic Influenza Uncertainty Geographical heterogeneity and influenza infection within households.Estimating the influenza vaccine effectiveness against medically attended influenza in clinical settings: a hospital-based case-control study with a rapid diagnostic test in Japan Effectiveness of MF59™ adjuvanted influenza A(H1N1)pdm09 vaccine in risk groups in the Netherlands.Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review Influenza vaccine effectiveness against hospitalisation with confirmed influenza in the 2010-11 seasons: a test-negative observational study Comparison of the epidemiology of laboratory-confirmed influenza A and influenza B cases in Manitoba, Canada Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses Evaluation of Microflow Digital Imaging Particle Analysis for Sub-Visible Particles Formulated with an Opaque Vaccine Adjuvant Nanoemulsion nasal adjuvant W₈₀5EC induces dendritic cell engulfment of antigen-primed epithelial cells.Influenza vaccine effectiveness in the community and the household Autoimmune Variant PTPN22 C1858T Is Associated With Impaired Responses to Influenza Vaccination.

P2860

Q27027029-1AB1C7C7-2BDB-4644-A235-44579BDD77F4 Q30224656-805D9D64-E886-4DAE-B69B-D9BE9772E019 Q30353821-7A44AFCA-DCA0-4D7C-94E8-A635CAC4903E Q30354181-98ED0B6B-C259-4C4B-B93C-EEEEE18EA4DE Q30356962-F8372303-7702-4A75-8607-10855D37DA04 Q30360483-7807D6F6-B465-4497-B247-0F59ED35E8E6 Q30364076-68291C19-A014-4BAF-A370-90055B312BD6 Q30367259-2188F8F4-93DA-43FF-97C4-CAFB2D42AF17 Q30367263-E7B7B78B-D83E-4388-9BC9-E1DE373E8488 Q30367695-61E040A4-EE31-42FB-8BD4-CA72C02F0938 Q30369467-9005982B-0B00-44B1-96F1-EDD0114BA73A Q30382343-5E6C59E3-1C6E-4404-A4BC-21919D678587 Q30392456-F494475F-39BB-4B85-873F-D3F7D7CC01DC Q30393380-D063A49A-ABCF-49A4-8C18-8B1B1511BB18 Q30402693-C197CFD7-5282-4701-91E4-57F16D24641F Q30406933-3C0D9A59-3696-45BB-86BC-9377951DE1C0 Q30410112-8DA8FE27-F350-4C15-8596-E73AF9F2F940 Q30410632-890BF10C-1461-4282-AF32-B8CA1CB5ED1E Q30411303-9864DBE7-9BEF-4873-9598-926E1F48F32A Q30411868-EFB00AEA-6CDB-4AFC-BF90-7D04EBD558E5 Q30412103-3D25BDB8-557F-4320-B2F2-66B260C33435 Q30413695-1392EE99-4DFF-423F-BA0F-1C125FA0AD77 Q30417417-08CB2CED-CDBB-4D15-97D3-15B32A4D9B2E Q30418277-53BEEF12-BD7A-4910-A5BE-590FAEEAE7F8 Q30419896-4F3B27B1-5E46-4A6D-BA7B-F8B4892263A9 Q30421507-3309EBBC-D056-4B29-89ED-D7FA1EB1F15B Q30421549-1827A44D-B5F8-4B4E-9138-5C4C6F1AFB3A Q30427049-96D094CC-BC96-46C5-A891-9E33D704470E Q30432474-51176A5D-815E-490B-AA1C-91D386FFCCC0 Q33891510-30AF364D-0471-4F61-B257-88BFE09D1E23 Q34550913-B4A85476-A401-47C6-9E8B-BDB4DC6D761D Q34707079-9997D345-706C-4E8B-BF28-1741C19BC37B Q34778408-2BDAA0C0-16EC-4144-9167-C33392364692 Q34850986-E98BC193-20DE-4941-AF9B-BE1D0A05C958 Q35091073-F7E82EDD-DDB6-4A8D-AEF1-2579BCC1D13F Q35130915-7A089CAD-28C2-4584-9821-2069D0B2FD21 Q35939390-0F6715FB-EE8C-42FC-A365-4DC4F390D4E3 Q36565552-50AED12E-F04F-4292-B503-07D00F264583 Q36956943-29027588-7FF9-45E5-A0C7-72B3B361DF9E Q37033053-F8F611BC-0DA5-48D1-A157-F2E8E39F2EF5

P2860

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.

http://www.wikidata.org/entity/Q30399334

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Effectiveness of AS03 adjuvant ...... system in Canada, autumn 2009.

@ast

Effectiveness of AS03 adjuvant ...... system in Canada, autumn 2009.

@en

type

label

Effectiveness of AS03 adjuvant ...... system in Canada, autumn 2009.

@ast

Effectiveness of AS03 adjuvant ...... system in Canada, autumn 2009.

@en

prefLabel

Effectiveness of AS03 adjuvant ...... system in Canada, autumn 2009.

@ast

Effectiveness of AS03 adjuvant ...... system in Canada, autumn 2009.

@en

P1433

Q30399334-D433105E-1E11-4907-94FC-75E4E93435C8

P1476

Q30399334-D4DA0DE4-B531-43FD-971C-AA2F39E4414F

P2093

Q30399334-27F9BE13-1B85-4CA5-A9D5-2414D7334CDD

Q30399334-44DE6C72-371C-4A5A-BB72-F37173190B02

Q30399334-505D6348-FE54-446C-8CB1-CE71662E53A0

Q30399334-96756200-8364-4CBA-A80C-3BECEF4487D7

Q30399334-DB9F7065-F3B2-4908-A53D-EC0875ABF472

P2860

Q30399334-15A445AD-3DDD-4E4B-8109-D26989C3E89E

Q30399334-32B97B64-2A5D-4123-934B-5DDFE82EA3D1

Q30399334-3869BD3A-BE2A-4A75-A411-DA729BC920AA

Q30399334-3F6D8A41-120A-406A-A18B-11081AB05FFC

Q30399334-7257F02B-B7F3-4467-BB5A-6813DD0581BA

Q30399334-82A90EE2-CC70-472F-B2EA-235320C2DABB

Q30399334-950634FD-EE9E-4417-8301-C382E3FC3671

Q30399334-B8861034-3E0B-4A4C-9379-ECD7C6D26C1A

Q30399334-BF310536-0405-4F4F-9EF5-DB3CD34767AF

Q30399334-D69F2A2F-C986-4BF2-96B0-E85E2154DDE8

P304

Q30399334-07A42C5C-7F7C-4AB6-A06F-F0E5D56F35F7

P31

Q30399334-3DABB3D7-2B0D-4A75-A730-88CD8A08E36B

P356

Q30399334-1F125746-DE41-48B7-A1A8-8CF3A2AEEB1A

P407

Q30399334-35F8BFEC-EE97-4ECD-B4C0-BEAB4AC57F7E

P478

Q30399334-FC08B6A0-9BE9-458E-90C9-DCBC78696F08

P50

Q30399334-1F0593E9-F21D-4E46-8D3A-729A637F86D5

Q30399334-220C9849-39BE-4592-9748-1A7C6F91CFCD

Q30399334-377F754D-97B0-417B-A34D-4106A15FECCA

Q30399334-9D8F9209-CC0F-4692-8F60-3272678801E2

Q30399334-9EAFBED9-980A-4C60-8D0A-72727AE7C8FC

Q30399334-ABC8E38F-BCDA-4890-A18C-665CE6DE08AF

Q30399334-B838570C-8B6B-45F2-9C8B-F3A8AE9F5991

Q30399334-DE654957-856F-4007-B50E-DFA5615E26FB

Q30399334-DF86B71B-4E6E-47E5-A960-3F62C26AFA67

P577

Q30399334-C7E376E1-E8E1-4CF3-BE2A-80F21E5CA959

P5875

Q30399334-8AEA2912-3B8B-46D5-B3AD-BA0310E2C160

P698

Q30399334-6513374D-7139-4F57-A065-DF06E5840B11

P921

Q30399334-1B2FD5DE-8523-488E-866D-E87402F16FD2

Q30399334-DCE6B39B-190A-48E2-80EC-F92FBA363E6F

P932

Q30399334-CB1452AE-BD9D-4679-A178-309357E428AF

P356

P1433

P1476

Effectiveness of AS03 adjuvant ...... system in Canada, autumn 2009.

@en

P2093

Danuta M Skowronski

http://www.w3.org/2001/XMLSchema#string

Kevin Fonseca

http://www.w3.org/2001/XMLSchema#string

Martin Petric

http://www.w3.org/2001/XMLSchema#string

Natasha Crowcroft

http://www.w3.org/2001/XMLSchema#string

Trijntje L Kwindt

http://www.w3.org/2001/XMLSchema#string

P2860

Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada.

Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada.

Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010.

Protective effect of single-dose adjuvanted pandemic influenza vaccine in children.

Vaccine effectiveness in pandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine.

Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.

Field evaluation of vaccine efficacy

An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination.

P304

c7297

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.C7297

http://www.w3.org/2001/XMLSchema#string

P407

P478

342

http://www.w3.org/2001/XMLSchema#string

P50

Naveed Zafar Janjua

James A Dickinson

Travis Salway Hottes

Nathalie Bastien

Gaston De Serres

Jonathan B Gubbay

P577

2011-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49809201

http://www.w3.org/2001/XMLSchema#string

P698

21292718

http://www.w3.org/2001/XMLSchema#string

P921

P932

3033439

http://www.w3.org/2001/XMLSchema#string